N-异丙基-3-氨基苯磺酰胺 | 118837-66-4

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-异丙基-3-氨基苯磺酰胺
• 中文别名: 3-氨基-N-异丙基苯磺酰胺
• 英文名称: 3-amino-N-(methylethyl)benzenesulfonamide
• 英文别名: 3-Amino-N-isopropylbenzenesulfonamide；3-amino-N-propan-2-ylbenzenesulfonamide
• CAS: 118837-66-4
• 化学式: C₉H₁₄N₂O₂S
• 分子量: 214.288
• InChiKey: NIUZLEBXTLRCKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Isopropyl 3-aminobenzenesulfonamide
Synonyms: 3-Amino-N-isopropylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Isopropyl 3-aminobenzenesulfonamide
CAS number: 118837-66-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14N2O2S
Molecular weight: 214.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-异丙基-3-氨基苯磺酰胺 在 吡啶 、 potassium phosphate 、 palladium diacetate 、 铁粉 、 氯化铵 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 31.0h， 生成 3-((5-chloro-2-((2-methoxy-4-(3-(pyridin-3-ylmethyl)ureido)phenyl)amino)pyrimidin-4-yl)amino)-N-isopropylbenzenesulfonamide
  参考文献：
  名称：

  带有N-（3-吡啶基甲基）尿素部分的新的2，4-二芳基氨基嘧啶衍生物作为间变性淋巴瘤激酶抑制剂的合成及抗肿瘤功效

  摘要：

  间变性淋巴瘤激酶（ALK）是负责各种肿瘤类型发展的受体酪氨酸激酶。在这项研究中，我们合成了一系列新型的2,4-二芳基氨基嘧啶衍生物，它们具有独特的N-（3-吡啶基甲基）脲作为ALK抑制剂。带有3-甲氧基-4-吗啉代苯基取代基的最有前途的类似物5m可显着抑制ALK阳性H3122和Karpas-299细胞的增殖，IC 50值约为10 nM，与阳性对照LDK378相当。化合物5m抑制ALK及其下游蛋白的磷酸化，并且对正常人原代成纤维细胞（BJ细胞）显示出低细胞毒性。装订方式5m由对接模拟提出，其解释了N-（3-吡啶基甲基）脲部分的重要作用。此外，在H3122异种移植小鼠模型中，化合物5m表现出良好的肝微粒体稳定性和显着的功效。有趣的是，化合物5m对其他人肿瘤细胞系也显示出更广泛的抗增殖活性，这与其他ALK抑制剂不同。

  DOI：

  10.1016/j.ejmech.2019.05.060
• 作为产物：
  描述：

  N-异丙基-3-硝基苯磺酰胺 在 palladium 10% on activated carbon 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以88%的产率得到N-异丙基-3-氨基苯磺酰胺
  参考文献：
  名称：

  [EN] POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
  [FR] PUISSANTS DOUBLES INHIBITEURS DE BRD4 ET DE KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX

  摘要：

  本文披露了一些抑制BRD4的化合物及其在癌症治疗中的应用。还披露了筛选BRD4选择性抑制剂的方法。在某些方面，披露了Formula I-IV的化合物。

  公开号：

  WO2016022460A1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013096153A1

  公开（公告）日：2013-06-27

  The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代喹啉衍生物。具体而言，本发明涉及根据公式I的化合物：其中R，R1，R2，R3和R4按如下定义。本发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢有关的疾病，例如癌症，更具体地说是乳腺癌、结肠癌、前列腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗与之相关的疾病的方法。
• [EN] POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] PUISSANTS DOUBLES INHIBITEURS DE BRD4 ET DE KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2016022460A1

  公开（公告）日：2016-02-11

  Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

  本文披露了一些抑制BRD4的化合物及其在癌症治疗中的应用。还披露了筛选BRD4选择性抑制剂的方法。在某些方面，披露了Formula I-IV的化合物。
• [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123738A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

  该发明涉及公式（I）中R1、R2、R3、R4、R5和p的化合物，其中这些参数在说明和权利要求中有定义，以及其药学上可接受的盐本身和作为药用活性物质，其制备方法，基于与该发明相符合的化合物的药物，以及它们的生产，以及在控制或预防上述疾病方面使用与该发明相符合的化合物，以及分别用于生产相应的药物。
• [EN] BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] INHIBITEURS DE BRD4-KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：H LEE MOFFITT CANCER CENTER & RES INST INC

  公开号：WO2017066428A1

  公开（公告）日：2017-04-20

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文披露了一些抑制BDR4的化合物及其在癌症治疗中的应用。还披露了筛选BDR4选择性抑制剂的方法。在某些方面，披露了公式I至IV的化合物。
• Pyrazolo-pyrimidine derivatives
  申请人：Goetschi Erwin

  公开号：US20050282827A1

  公开（公告）日：2005-12-22

  The invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined in the description and to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, to the manufacture of such compounds and compositions, and to methods of treating or preventing acute and/or chronic central nervous system disorders by administering such compounds.

  本发明涉及公式(I)的化合物，其中R1、R2、R3、R4、R5和p如描述中所定义的，并且涉及其药学上可接受的盐，含有这种化合物的制药组合物，制造这种化合物和组合物的方法，以及通过给予这种化合物来治疗或预防急性和/或慢性中枢神经系统疾病的方法。